Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)

Inclusion Criteria: * Patients with relapsed PTCL according to WHO criteria who have received max. two previous treatments for PTCL * Age ≥ 18 years. * Adequate bone marrow function i.e. absolute neutrophile count of \> 1000/µl and thrombocytes \> 75,000/µl. * Alkaline phosphatase and transaminases ≤ 2,5 x upper limit of normal (ULN) * Total bilirubin ≤ 2,5 x ULN * Creatinine clearance ≥ 50 ml/min * Female subjects of childbearing potential† must: Understand that the study medication could have an expected teratogenic risk and agree to use, and be able to comply with, effective contraception and agree to have a medically supervised pregnancy test * Male subjects must agree to use condoms and agree not to donate semen Exclusion Criteria: * Prior history of malignancies, other than PTCL, unless the subject has been free of the disease for ≥ 3 years * Prior allogeneic bone marrow transplant or plans to undergo autologous/ allogeneic bone marrow transplant within 4 weeks of the initiation of vorinostat administration * Prior treatment with a HDAC inhibitor * Prior treatment with Lenalidomide (patients previously treated with Thalidomide may be enrolled) * Known history of Deep Vein Thrombosis (DVT) and/ or pulmonary embolism (PE)